

Our ref: FOI 1483

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

Information regarding meeting minutes for Drug Therapeutics and Guidelines Committee has now been considered and the information requested is enclosed.

Dear Southern Health and Social Care Trust (Northern Ireland),

I am writing to request information under the Freedom of Information Act regarding the latest Meeting Minutes of your one committee.

Could you please provide the latest meeting minutes for;

1) Drug Therapeutics and Guidelines Committee at Southern Health and Social Care Trust (SHSCT)?

If you have any further questions regarding my request, please let me know!

### **Medicines Optimisation / Drug and Therapeutics Committee 8<sup>th</sup> December 2022**

Attendance: Damian Gormley\*, Ann McCorry\*, Janet Lawson, Maria McConnell, Brian Maguire\*, Stephanie Hunter\*, Peter Sharpe\*, Rose McCullagh\*.

\*attended meeting on 12<sup>th</sup> January 2023 to finalise outstanding issues.

#### **Action Notes**

Item	Subject	Action
1	Apologies – Rose McCullagh, Peter Sharpe, Grace Hamilton, Damian Scullion.	Stephanie Hunter in attendance for Grace.
2	Minutes of previous meeting - Sept 2022	Accepted.  Matters arising: <ul style="list-style-type: none"><li>• Community Administration sheet- awaiting update from MH.</li><li>• New product form updated and on sharepoint.</li><li>• MST information sheet will be updated as suggested on next regional update</li></ul>

		<ul style="list-style-type: none"> <li>Chloral Hydrate- on agenda</li> </ul>
3	<p>Medicines Governance reports</p> <p>a. Quarterly Report July to Sept 2022</p>	<p>a. Papers presented by MMCC and discussed.</p> <p>No new trends and action plans in place for the moderate incidents.</p> <p>Never event regarding medical air- under investigation, SAI.</p> <p>Never event of oral CD medication administered IV discussed- action plan of previous SAI involving S/C administration to be considered during this review.</p>
4	<p>New product requests</p> <p>a. Cefepime</p> <p>b. Clozapine Inj (unlicensed) – approved via email, for information.</p> <p>c. Proprems probiotic supplement.</p>	<p>a. Approved for use for pseudomonas treatment on microbiology advice pending comments from other members. <b>Jan update: no comments received, approved.</b></p> <p>b. Approved via email for urgent use in September for one patient.</p> <p>c. Requires discussion-defer to next meeting. <b>Jan update:- MI team provided update-used nationally in NHS and meets requirements of probiotic content required.</b> <b>No Paediatric representation at the meeting- await update form Julie McConville with further information to be emailed to members before final decision.</b></p>
5	<p>Specialist Medicines update</p> <p>a. Red amber adjudications</p> <p>b. Update on local and regional activity</p>	<p>a. 2486 Abrocitinib 2830 Fondaparinux 1440 Metreleptin</p> <p>b. A lot of adjudications including the cross speciality group .</p> <p>Endorsement of Regional Shared Care Guidelines and GP Information Sheets for Amber Medicines</p> <p>Shared-care arrangements for specialist medicines enable GPs to prescribe amber list specialist medicines by providing the GP with the necessary information and support to do so safely and effectively.</p> <p>The Group have endorsed Shared Care Guidelines for the following medicines to support effective shared-care arrangements, and provide consistency in approach. Implementation should now be brought forward at local level. <a href="http://www.ipnsm.hscni.net">www.ipnsm.hscni.net</a></p>



		<p>Drug Indication(s) liothyronine</p> <p>JL meeting with GP Federation Pharmacists next week and will prepare an update for circulation within the Trust as a reminder of Shared Care Guideline requirements.</p>
6	<p>Clinical Guidelines for approval</p> <ol style="list-style-type: none"> <li>a. Insulin titration guidance</li> <li>b. Chloral Hydrate Shared care Guideline</li> <li>c. Paediatric Gentamicin Prescription Chart</li> <li>d. NRT PGD for staff</li> <li>e. NRT prescription</li> <li>f. Homecare PIL</li> <li>g. IBD Infliximab Clinical Protocol</li> <li>h. Physician Associate administration of medications protocol</li> <li>i. Physicians Associate administration of medication competency framework</li> <li>j. Misuse and Safe Disposal of Medicines- updated procedures</li> <li>k. Updated Medicines Code</li> </ol>	<ol style="list-style-type: none"> <li>a. Approved-remove/add abbreviations. <b>Jan update: final version will be submitted for March approval.</b></li> <li>b. Approved-needs alternative title. <b>Jan update: Renamed to GP information sheet, approved.</b></li> <li>c. Approved.</li> <li>d. For further discussion regarding need for both PGD and prescription to enable service to continue. Referral process and additional supply process to be clarified. <b>Jan update: currently only 1 nurse in post, who is a prescriber so PGD not required at present. To be discussed with service lead if to be added to current PGDs as due for renewal. Staff can self-refer and will be reviewed.</b></li> <li>e. Need to update with allergy box. <b>Jan update-prescription approved pending review by medicines governance pharmacist.</b></li> <li>f. Hold- pending PPI sign off and agreement on process how will be supplied.</li> <li>g. Hold-AMC to confirm with Una regarding changes and if possible to have 1 protocol for all areas, with MI approval required. <b>Jan update- On discussion with Una, contents as per SPC and IBD specific, approved. Reference to 'policy' to be removed. MI to review and send final comments before use.</b></li> <li>h. SH and Directorate nurses to review and discuss.</li> <li>i. As above</li> <li>j. Hold- requires discussion with wider group- defer until next meeting or Jan. <b>Jan update: changes discussed and approved- likely implementation Feb/Mar 23.</b></li> <li>k. Full update deferred, will update relevant sections regarding CDs and PA's as required.</li> </ol>
7	<p>HSCB and DoH Items</p> <ol style="list-style-type: none"> <li>a. Update from Southern Area Prescribing &amp; Medicines Management Committee</li> </ol>	<ol style="list-style-type: none"> <li>a. Lidocaine and enoxaparin memo has been circulated within the Trust. Individual issues with enoxaparin followed up with prescribing teams. Chloral "shared care" document approval for use.</li> </ol>

	<ul style="list-style-type: none"> <li>b. Agreement to Apply NI Formulary Chapter 11 Eye</li> <li>c. Prescribing of Proton Pump Inhibitors (PPIs) and H2-receptor antagonists (H2RA)</li> </ul>	<ul style="list-style-type: none"> <li>b. Final documents attached for use within the Trust. AMC to check with ED/MIU regarding leaflets and check if link can be added to clinical guideline site.</li> <li>c. Targeted distribution through GI teams.</li> </ul>
8	<p>Committee/Audit updates</p> <ul style="list-style-type: none"> <li>a. NMP Committee- Updated Framework</li> <li>b. Pharmacy Internal audit</li> </ul>	<ul style="list-style-type: none"> <li>a. Agreed. NMP committee to send update on workplan to D&amp;T.</li> <li>b. BSO internal audit completed- audit report actions discussed.</li> </ul>
9	<p>Any other business</p> <ul style="list-style-type: none"> <li>a. ToR</li> <li>b. Parkinson's Time Critical Medication Campaign</li> <li>c. 2023 meeting dates</li> <li>d. Jan meeting</li> </ul>	<ul style="list-style-type: none"> <li>a. ToR to be finalised. <b>Jan update- final version agreed.</b></li> <li>b. Discussed-commitment from the Trust to the principals. MMCC will update on regional workload.</li> <li>c. Agreed <b>Jan update- discussion around low attendance rates. Suggested trial of meeting either Thurs pm or Wed am- new meeting dates to be circulated.</b></li> <li>d. For approval of outstanding items</li> </ul>
10	Date of next meeting	9 <sup>th</sup> March 2023 2pm-4pm